ASTRAZEN · NSE
AstraZeneca Pharma India Limited
₹6,751.5
+1.24% (+₹82.5)
Prev. close
₹6,669
Volume
4,635
Delivery %
60.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cancers, including pancreatic cancer, certain blood cancers, and cancers within breast, lung, ovary, and prostate; rare diseases; and cardiovascular, renal and metabolism, and respiratory and immunology, as well as diabetes. The company serves distributors, hospitals, and government institutions. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Praveen Rao Akkinepally
Headquarters
Bengaluru
Employees
600
Website
astrazeneca.inExchange
View on NSE ↗Key stats
Market cap
₹16,672.50 Cr
P/E ratio (TTM)
98.5
Dividend yield
0.54%
EPS (TTM)
₹67.70
Beta (1Y · daily vs NIFTY 50)
0.54
Beta (5Y · monthly vs NIFTY 50)
0.94
Shares float
46.09 L
EPS · quarter ended Jun 2026
₹15.17
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: Yahoo (no NSE corporate-actions ledger for this listing).
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹813.56 Cr | ₹805.60 Cr | ₹1,002.97 Cr | ₹1,295.53 Cr | ₹1,716.29 Cr | ₹2,275.58 Cr | |
| EBITDA | ₹148.31 Cr | ₹100.93 Cr | ₹151.00 Cr | ₹235.68 Cr | ₹197.81 Cr | ₹285.27 Cr |
| ₹93.30 Cr | ₹61.59 Cr | ₹99.29 Cr | ₹161.51 Cr | ₹115.74 Cr | ₹187.52 Cr | |
| Diluted EPS | ₹37.32 | ₹24.64 | ₹39.7 | ₹64.6 | ₹46.3 | ₹75 |
Other income has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹775.00 Cr | ₹857.00 Cr | ₹985.00 Cr | ₹1,078.00 Cr | ₹1,518.00 Cr | ₹1,989.00 Cr | |
| — | — | ₹7.21 Cr | ₹4.59 Cr | ₹35.73 Cr | ₹110.66 Cr | |
| Stockholders' equity | ₹456.00 Cr | ₹511.00 Cr | ₹589.00 Cr | ₹712.00 Cr | ₹770.00 Cr | ₹873.00 Cr |
Current assets, Inventory, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹105.00 Cr | ₹101.00 Cr | ₹58.00 Cr | ₹28.00 Cr | ₹65.00 Cr | ₹-15.00 Cr | |
| Investing cash flow | ₹173.03 Cr | ₹4.74 Cr | ₹18.11 Cr | ₹21.74 Cr | ₹30.80 Cr | ₹18.69 Cr |
| ₹-8.98 Cr | ₹-9.46 Cr | ₹-24.48 Cr | ₹-44.37 Cr | ₹-65.59 Cr | ₹-91.97 Cr | |
| Capital expenditure | ₹-7.71 Cr | ₹-9.62 Cr | ₹-8.52 Cr | ₹-10.76 Cr | ₹-1.75 Cr | ₹-3.61 Cr |
| End cash position | ₹352.34 Cr | — | ₹500.34 Cr | ₹505.57 Cr | ₹536.14 Cr | ₹447.72 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 75.00% |
| Public | 25.00% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| AstraZeneca Pharma India Limited | ₹16,887.50 Cr | ₹6,764.5 | 99.9 | 19.35 | 21.5% | 0.13 | +32.6% | -24.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
8 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Why did AstraZeneca Pharma Exit Oncology and Biopharmaceuticals Manufacturing Despite Being the Majority Revenue Growth Driver?
AstraZeneca Pharma India is shifting its business model from domestic manufacturing to importing specialized medicines from its parent company. This strategic move aims to accelerate growth by focusing on high-growth areas like oncology and biopharmaceuticals, despite winding down its Bengaluru manufacturing facility. The company believes acting as a distribution arm for global R&D will yield better returns than domestic production.